Patents/Assignees

SPRINGWORKS THERAPEUTICS, Inc.

37 patents in portfolio

US12599587utility2026
Chlorinated Tetralin Compounds and Pharmaceutical Compositions
0 cites
US12570752utility2026
Combination Therapy with an Anti BCMA Antibody and a Gamma Secretase Inhibitor
0 cites
US12390430utility2025
Mirdametinib Treatment
0 cites
US12357597utility2025
Dispersible Formulations of N-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benazmide and Uses Thereof
0 cites
US12324791utility2025
Mirdametinib Treatment
0 cites
US12295925utility2025
Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) in Pediatric Patients with Mirdametinib
0 cites
US12275688utility2025
Crystalline Solids of MEK Inhibitor N-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benzamide and Uses Thereof
0 cites
US12263146utility2025
Non-linear Dosing of Mirdametinib
0 cites
US12257215utility2025
Mirdametinib Treatment
0 cites
US12247012utility2025
Synthesis of Nirogacestat
0 cites
US12234210utility2025
Synthesis of Nirogacestat
0 cites
US12220390utility2025
Mirdametinib Treatment
0 cites
US12186305utility2025
Treatments with Nirogacestat
0 cites
US12138246utility2024
Treatments with Nirogacestat
0 cites
US12110277utility2024
Synthesis of Nirogacestat
0 cites
US12090128utility2024
Dispersible Formulations of N-((r)-2,3-dihydroxypropoxy)-3,4-difluoro-2-(2-fluoro-4-iodo-phenylamino)-benazmide and Uses Thereof
0 cites
US12036207utility2024
Treatments with Nirogacestat
0 cites
US12029711utility2024
Dosage Forms of Mirdametinib
0 cites
US12011424utility2024
Treatment of Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) in Pediatric Patients with Mirdametinib
0 cites
US12011434utility2024
Treatments with Nirogacestat
0 cites

Page 1 of 2Next →